23,519 Shares in Harrow, Inc. $HROW Bought by Militia Capital Management LLC

Militia Capital Management LLC acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 23,519 shares of the company’s stock, valued at approximately $829,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HROW. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Harrow in the fourth quarter valued at about $26,000. KBC Group NV purchased a new stake in shares of Harrow during the first quarter worth about $31,000. Raymond James Financial Inc. acquired a new position in shares of Harrow during the 2nd quarter worth about $48,000. SBI Securities Co. Ltd. raised its position in shares of Harrow by 393.5% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after purchasing an additional 846 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after buying an additional 369 shares in the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Stock Performance

NASDAQ:HROW opened at $38.77 on Monday. The company has a market cap of $1.45 billion, a P/E ratio of -94.56 and a beta of 0.26. Harrow, Inc. has a twelve month low of $28.54 and a twelve month high of $54.85. The company’s 50-day moving average price is $39.81 and its 200-day moving average price is $40.36. The company has a current ratio of 2.48, a quick ratio of 2.30 and a debt-to-equity ratio of 10.30.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.31). The business had revenue of $44.20 million for the quarter, compared to analysts’ expectations of $52.43 million. Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. During the same period in the prior year, the company posted ($0.38) EPS. On average, sell-side analysts forecast that Harrow, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Harrow

In related news, CFO Andrew R. Boll purchased 3,500 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was acquired at an average cost of $29.90 per share, for a total transaction of $104,650.00. Following the completion of the transaction, the chief financial officer directly owned 814,679 shares of the company’s stock, valued at approximately $24,358,902.10. This trade represents a 0.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Adrienne L. Graves purchased 1,000 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was bought at an average cost of $31.07 per share, with a total value of $31,070.00. Following the acquisition, the director owned 1,000 shares of the company’s stock, valued at approximately $31,070. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 12.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on HROW shares. Cantor Fitzgerald lowered their price objective on Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. B. Riley Financial reissued a “buy” rating and set a $65.00 target price (down from $74.00) on shares of Harrow in a report on Tuesday, April 7th. Wall Street Zen downgraded Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating and issued a $63.00 price target on shares of Harrow in a research note on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research report on Monday, July 20th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $69.43.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.